# Exelon

NDC: 0078-0502
Generic name: rivastigmine
Labeler / Manufacturer: Novartis Pharmaceuticals Corporation
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: PATCH, EXTENDED RELEASE
Routes: TRANSDERMAL
Marketing started: 20070706
Marketing ended: 20261231
FDA application: NDA022083

## Active ingredients

- RIVASTIGMINE: 9.5 mg/24h

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0078-0502"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0078-0502
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0